Curetis N.V. secured equity funding of EUR 8.9 million – goetzpartners securities advised on private placement

Curetis N.V. (Euronext: CURE) announced on 7 November, 2018 that it had successfully placed 4,450,000 new ordinary shares with institutional investors at an offer price of EUR 2.00 per share, raising in total gross proceeds of EUR 8.9 million despite challenging market conditions. The funds are expected to be allocated to (i) the commercialization of its Unyvero Platform and LRT Application Cartridge in the U.S., (ii) its European commercialization activities, (iii) working capital requirements, (iv) research and development programs and (v) general corporate purposes. 

The new shares were sold by way of a private placement to institutional investors in Europe and the U.S. (including certain existing shareholders) in compliance with applicable securities laws. With the completion of the transaction the number of registered shares of Curetis increased to 20,908,802.

goetzpartners securities Limited was acting as Co-manager in the private placement.

ABOUT CURETIS

Curetis N.V. is focused on providing innovative solutions for molecular microbiology diagnostics designed to diagnose severe infectious diseases and identify antibiotic resistances in hospitalized patients. Curetis is located in Holzgerlingen, Germany. The Company is listed on Euronext Amsterdam and Euronext Brussels under ISIN NL0011509294 and ticker symbol CURE. Visit www.curetis.com for additional information on Curetis.

TRANSACTION TEAM

Wolf Dornbusch
Director
Email

Youchen Xin
Associate

Erland Sternby
Marketing Sales